Triplex formation inhibits HER-2/neu transcription in vitro.
Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Donald M. Miller(University of Louisville), Charles A. Mayfield(Baylor College of Medicine), Jay E. Gee(Baylor College of Medicine), Brad Rodu(Baylor College of Medicine), Glenn M. Sanders(Baylor College of Medicine)
Cited by 81
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k